Long-interval T2-weighted subtraction magnetic resonance imaging: A powerful new outcome measure in multiple sclerosis trials

Annals of Neurology

Volumn 67, Issue 5, 2010, Pages 667-675

  Moraal, Bastiaan ^a   Van Den Elskamp, Ivo J ^a   Knol, Dirk L ^a   Uitdehaag, Bernard M J ^a   Geurts, Jeroen J G ^a   Vrenken, Hugo ^a   Pouwels, Petra J W ^a   Van Schijndel, Ronald A ^a   Meier, Dominik S ^b   Guttmann, Charles R G ^b   Barkhof, Frederik ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; PLACEBO; TEMSIROLIMUS;

ADULT; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; FEMALE; HUMAN; IMAGE SUBTRACTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SAMPLE SIZE; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 77951750526     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Willoughby EW, Grochowski E, Li DK, et al. Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients. Ann Neurol 1989;25:43-49. (Pubitemid 19032841)
2. Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991;29:53-62.
3. Kermode AG, Thompson AJ, Tofts P, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain 1990;113:1477-1489.
4. Nesbit GM, Forbes GS, Scheithauer BW, et al. Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy. Radiology 1991;180:467-474.
5. Harris JO, Frank JA, Patronas N, et al. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 1991;29:548-555.
6. Guttmann CR, Ahn SS, Hsu L, et al. The evolution of multiple sclerosis lesions on serial MR. AJNR Am J Neuroradiol 1995;16:1481-1491.
7. Ledneva E, Karie S, Launay-Vacher V, et al. Renal safety of gadolinium-based contrast media in patients with chronic renal insufficiency. Radiology 2009;250:618-628.
8. Wertman R, Altun E, Martin DR, et al. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology 2008;248:799-806.
9. Molyneux PD, Filippi M, Barkhof F, et al. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann Neurol 1998;43:332-339. (Pubitemid 28113596)
10. Goodkin DE, Vanderburg-Medendorp S, Ross J. The effect of repositioning error on serial magnetic resonance imaging scans. Arch Neurol 1993;50:569-571.
11. Tan IL, van Schijndel RA, Fazekas F, et al. Image registration and subtraction to detect active T(2) lesions in MS: an interobserver study. J Neurol 2002;249:767-773.
12. Moraal B, Meier DS, Poppe PA, et al. Subtraction MR images in a multiple sclerosis multicenter clinical trial setting. Radiology 2009;250:506-514.
13. Duan Y, Hildenbrand PG, Sampat MP, et al. Segmentation of subtraction images for the measurement of lesion change in multiple sclerosis. AJNR Am J Neuroradiol 2008;29:340-346. (Pubitemid 351287893)
14. Kappos L, Barkhof F, Desmet A. The effect of oral temsirolimus on new magnetic resonance imaging scan lesions, brain atrophy, and the number of relapses in multiple sclerosis: results from a randomised, controlled trial. J Neurol 2005;252(supplement 2):46.
15. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol 1996;39:6-16. (Pubitemid 26052212)
16. Smith SM. Fast robust automated brain extraction. Hum Brain Mapp 2002;17:143-155.
17. Smith SM, Jenkinson M, Woolrich MW, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004;23:S208-S219. (Pubitemid 39421720)
18. Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging 1998;17:87-97.
19. Jenkinson M, Smith S. A global optimisation method for robust affine registration of brain images. Med Image Anal 2001;5:143-156. (Pubitemid 35282800)
20. Barkhof F, Filippi M, van Waesberghe JH, et al. Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis. Neurology 1997;49:1682-1688. (Pubitemid 28015137)
21. McAuliffe M, Lalonde E, McGarry D, et al. Medical image processing, analysis and visualization in clinical research. In: Proceedings of the 14th IEEE symposium on computer-based medical systems. Los Alamitos, CA: IEEE Computer Society, 2001:381-386.
22. Sormani MP, Miller DH, Comi G, et al. Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets. J Neurol Neurosurg Psychiatry 2001;70:494-499. (Pubitemid 32269687)
23. Sormani MP, Bruzzi P, Miller DH, et al. Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials. J Neurol Sci 1999;163:74-80. (Pubitemid 29155420)
24. van den Elskamp I, Knol D, Uitdehaag B, Barkhof F. The distribution of new enhancing lesion counts in multiple sclerosis: further explorations. Mult Scler 2009;15:42-49.
25. Tubridy N, Barker GJ, Macmanus DG, et al. Three-dimensional fast fluid attenuated inversion recovery (3D fast FLAIR): a new MRI sequence which increases the detectable lesion load in multiple sclerosis. Br J Radiol 1998;71:840-845. (Pubitemid 28391084)
26. Tan IL, Pouwels PJ, van Schijndel RA, et al. Isotropic 3D fast FLAIR imaging of the brain in multiple sclerosis: initial experience. Eur Radiol 2002;12:559-567.
27. Moraal B, Roosendaal SD, Pouwels PJ, et al. Multi-contrast, isotropic, single-slab 3D MR imaging in multiple sclerosis. Eur Radiol 2008;18:2311-2320. (Pubitemid 351508085)
28. Mugler JP III, Bao S, Mulkern RV, et al. Optimized single-slab three-dimensional spin-echo MR imaging of the brain. Radiology 2000;216:891-899. (Pubitemid 30660871)
29. Kallmes DF, Hui FK, Mugler JP III. Suppression of cerebrospinal fluid and blood flow artifacts in FLAIR MR imaging with a single-slab three-dimensional pulse sequence: initial experience. Radiology 2001;221:251-255.
30. Cotton F, Weiner HL, Jolesz FA, Guttmann CR. MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 2003;60:640-646. (Pubitemid 36246083)
31. Barkhof F, Scheltens P, Frequin ST, et al. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. AJR Am J Roentgenol 1992;159:1041-1047.
32. Miller DH, Barkhof F, Nauta JJ. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 1993;116:1077-1094. (Pubitemid 23329882)
33. Barkhof F, Held U, Simon JH, et al. Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials. Neurology 2005;65:1447-1454. (Pubitemid 41552778)
34. Barkhof F, Valk J, Hommes OR, Scheltens P, Nauta JJ. Gadopentetate dimeglumine enhancement of multiple sclerosis lesions on long TR spin-echo images at 0.6 T. AJNR Am J Neuroradiol 1992;13:1257-1259.
35. Basile AM, Pantoni L, Pracucci G, et al. Age, hypertension, and lacunar stroke are the major determinants of the severity of age-related white matter changes. The LADIS (Leukoaraiosis and Disability in the Elderly) Study. Cerebrovasc Dis 2006;21:315-322.
36. Vernooij MW, Ikram MA, Tanghe HL, et al. Incidental findings on brain MRI in the general population. N Engl J Med 2007;357:1821-1828. (Pubitemid 350044802)